Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update
10 nov. 2022 06h59 HE
|
Synlogic, Inc.
Top-line Phase 2 data for phenylketonuria (PKU) demonstrated robust plasma Phe reduction and high response rate; Phase 3 study initiation planned for H1 2023 Clinical readouts for SYNB1353 for...
Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3
18 oct. 2022 06h59 HE
|
Synlogic, Inc.
Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of...
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria
24 mai 2022 07h00 HE
|
Synlogic, Inc.
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
FIXX NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Homology Medicines, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FIXX
26 avr. 2022 11h24 HE
|
The Rosen Law Firm PA
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June...
ROSEN, A LONGSTANDING LAW FIRM, Encourages Homology Medicines, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FIXX
31 mars 2022 17h15 HE
|
The Rosen Law Firm PA
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
American Gene Technologies to Present at 2020 Inborn Errors of Metabolism Drug Development Summit in Boston
10 mars 2020 09h34 HE
|
American Gene Technologies
ROCKVILLE, Md., March 10, 2020 (GLOBE NEWSWIRE) -- American Gene Technologies (AGT), a leading gene and cell therapy company in Rockville, Maryland, is pleased to announce its Chief Science Officer C....
Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria
30 janv. 2020 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference
13 janv. 2020 08h00 HE
|
Rubius Therapeutics
RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration Rubius Manufacturing Facility Operational Nine Months Ahead of Schedule and Ready to Supply...
Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer
08 janv. 2020 08h00 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
02 janv. 2020 16h05 HE
|
Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...